- Trials with a EudraCT protocol (124)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
124 result(s) found for: Adiposity.
Displaying page 7 of 7.
EudraCT Number: 2018-002431-18 | Sponsor Protocol Number: NN9536-4451 | Start Date*: 2019-09-25 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity | ||||||||||||||||||
Medical condition: Overweight Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) IE (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-006184-19 | Sponsor Protocol Number: SPI-62-CL-2001 | Start Date*: 2022-06-22 | |||||||||||
Sponsor Name:Sparrow Pharmaceuticals, Inc. | |||||||||||||
Full Title: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome | |||||||||||||
Medical condition: Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001945-14 | Sponsor Protocol Number: NN9838-4433 | Start Date*: 2019-01-10 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Investigation of safety and efficacy of NNC0174-0833 for weight management – a dose finding trial | ||||||||||||||||||
Medical condition: Obesity Overweight | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) DK (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005855-35 | Sponsor Protocol Number: U1111-1270-0943 | Start Date*: 2023-01-10 | ||||||||||||||||
Sponsor Name:NOVO NORDISK. S.P.A. | ||||||||||||||||||
Full Title: The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascu... | ||||||||||||||||||
Medical condition: Atherosclerotic cardiovascular disease and Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) NL (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
